Optiver Holding
HRTX icon

Optiver Holding’s Heron Therapeutics HRTX Stock Holding History

Optiver Holding’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$728 Buy
1,706
+1,312
+333% +$1.05K ﹤0.01% 2540
2026
Q1 		$315 Sell
394
-694
-64% -$804 ﹤0.01% 2204
2025
Q4 		$1.41K Sell
1,088
-794
-42% -$980 ﹤0.01% 2137
2025
Q3 		$2.37K Sell
1,882
-1
-0.1% -$2 ﹤0.01% 2317
2025
Q2 		$3.9K Buy
1,883
+1,459
+344% +$2.98K ﹤0.01% 1247
2025
Q1 		$933 Buy
+424
New +$823 ﹤0.01% 1281
2024
Q4 		– Sell
-1,005
Closed -$2K – 1103
2024
Q3 		$2K Sell
1,005
-800
-44% -$1.91K ﹤0.01% 867
2024
Q2 		$6.32K Buy
+1,805
New +$5.54K ﹤0.01% 775

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Optiver Holding's HRTX Position: Q2 2026 in Review

Optiver Holding increased its Heron Therapeutics (HRTX) stake by 333% in Q2 2026, buying an estimated $1.05K and bringing the position to 1,706 shares worth $728. The position accounts for ﹤0.01% of the portfolio, ranked #2540.

Optiver Holding first reported a position in HRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.32K in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Optiver Holding held 1,706 shares of Heron Therapeutics worth $728 as of Q2 2026.
  • Optiver Holding bought 1,312 Heron Therapeutics shares in Q2 2026, an estimated $1.05K.
  • Heron Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2540 holding.
  • Optiver Holding first reported a position in Heron Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Optiver Holding's Heron Therapeutics position peaked at $6.32K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.